Navigation Links
Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development
Date:4/24/2013

rgic asthma" by Kai-Michael Beeh , MD, et al. The article was selected for comment by the JACI Editors ("The Editors' Choice") under the heading "Get the balance right - therapeutic immune modulation in patients with allergic asthma".

Financial Results

Three-month period from January 1 to March 31, 2013

On March 31, 2013, funds available for financing the operations (including cash, cash equivalents, financial assets and trade and other receivables) amounted to CHF 23.58 million. The funds were CHF 5.07 million less than on December 31, 2012 (CHF 28.65 million) primarily due to expenses incurred in ongoing operating activities.

On March 31, 2013, the nominal value of convertible bonds not held by the Company amounted to CHF 13.17 million. Cytos did not buy back any convertible bonds on the market during the first quarter of 2013.

Revenue comprising deferred income from licence fees paid by Novartis of CHF 0.25 million has been recognized in the first quarter 2013, unchanged from the first quarter 2012.

The gross cash burn for operating activities, as calculated on the cash flow statement, was CHF 1.72 million on average per month in the first three months of 2013, compared to CHF 1.04 million on average per month in the first quarter of 2012.

Financial summary (IFRS, consolidated)

(in CHF million) Q1 2013 Q1 2012 Revenue 0,3 0,3 Net operating cost (4,0) (3,0) Operating loss (3,7) (2,8) Net (loss) / income (5,4) 2,5 Net (loss) / income per share (in CHF) (0,24) 0,47 December 31, (in CHF million) March 31, 2013 2012 Cash, cash equivalents, financial assets as well as trade and other receivables 23,6 28,7 Full-time equivalents 22,5 20,9

The detailed Q1 Financial Report 2013 can be downloaded at

http://www.cytos.com/uploads/2013/Cytos_Quarter_1_2013_E.pdf
'/>"/>

SOURCE Cytos Biotechnology Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnologys CYT003 for the Treatment of Allergic Asthma
2. Cytos Biotechnology Strengthens Management Team
3. Plandai Biotechnology, Inc. Announces Shipment Of First Machinery To South African Production Facility
4. PharmaLeaders: Innovative Mid-Cap Biotechnology Benchmark Report - Financial Benchmarking, Pipeline Assessment & Competitive Analysis of Innovative Biotechs
5. Choose New Jersey and Partners to Promote New Jersey As Global Life Science Hub at Worlds Largest Biotechnology Event
6. Plandai Biotechnology, Inc. Enters Into License Agreement With Phyto Nutricare To Develop Nutraceutical Products
7. Biotechnology Market (Biopharmacy, Bioservices, Bioagri, Bioindustrial) Is Expected to Reach USD 414.5 Billion Globally in 2017: Transparency Market Research
8. NanoSight, One of the UKs Fastest Growing Biotechnology Companies, Wins a 2013 Queens Award for Enterprise - Innovation
9. Global Biotechnology Industry Market Research Report Now Available from IBISWorld
10. Plandai Biotechnology, Inc. Updates Progress Of Preparing Products For Market
11. San Diego State University Hosts Open House for Life Science Immersion Biotechnology Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... -- TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer ... agreement whereby the institutional investors will have the option ... Company up to $4.93M in near term funding, pending ... the restructured terms and subject to certain market conditions, ... result in a larger influx of capital to fund ...
(Date:6/2/2015)... 2, 2015 /CNW/ - Shell today celebrated the North American ... category with an exhibit the size of a city ... demonstrations for media and the public, and special appearances ... Premium Gasoline provides the best total engine protection by ... wear, gunk and corrosion. "With the launch ...
(Date:6/2/2015)... and TORONTO , June 2, ... TSX: APS), a clinical-stage company developing new therapeutics that ... the U.S. Food and Drug Administration (FDA) has granted ... treatment of acute myeloid leukemia (AML). APTO-253, a first-in-class ... product candidate in a Phase Ib clinical trial in ...
(Date:6/2/2015)... June 02, 2015 Global Stem Cells ... distributor for Bioquark, Inc.’s biologic products for the regeneration and ... latest in Global Stem Cells Group’s ambitious expansion plans in ... demand for access to regenerative medicine and stem cell therapies. ... development of biologics that have the ability to alter the ...
Breaking Biology Technology:TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 3New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 2New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 3New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 4Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 2Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 3Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 4Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 2Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 3
... (Nasdaq: MSHL ), an oncology company focused on ... today that Charles Baltic, Managing Director and Co-Head of Healthcare ... of directors. The appointment of Mr. Baltic increases the number ... directors to five. "On behalf of the entire ...
... /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China ... biopharmaceutical companies in the People,s Republic of China, today ... annual list of Asia,s "200 Best Under a Billion" ... to the same list for the year 2009. ...
... Conn., Oct. 24, 2011 Modern Plastics, one of ... and medical-grade plastics, has become ISO 13485-2003 certified for ... Film and Resin. "This is an ... commitment to service and quality," said Bing J. Carbone, ...
Cached Biology Technology:Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 2Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 3China Biologic Named to Asia's "200 Best Under a Billion" by Forbes Asia 2China Biologic Named to Asia's "200 Best Under a Billion" by Forbes Asia 3
(Date:6/1/2015)... June 1, 2015 According to ... Sensing Market by Technology (Touch-based & Touchless), Application (Consumer ... & by Geography - Global Forecast to 2020", published ... is expected to reach $23.55 Billion by 2020, at ... Browse 83 market data T ables ...
(Date:6/1/2015)... 2015 According to a ... by Application (Government, Military & Defense, Healthcare, Banking ... Security), Technology (Face Recognition, Fingerprint Recognition, Iris Recognition, ... and Others), Function (Contact and Non-Contact) & Geography ... Europe , APAC, Row) - Global Forecast ...
(Date:5/29/2015)... , May 28, 2015 Research and ... of the "Facial Recognition Market by Solution, ... Global Forecast to 2020" report to their ... seen facial recognition technology become more efficient and ... gain traction and investment from the commercial sector. ...
Breaking Biology News(10 mins):Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 2Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 3Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 4Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2
... like Alzheimer,s, Parkinson,s and Creutzfeldt-Jakob disease. But amyloid ... the development of new composite materials for the ... even make objects invisible. Researchers from Chalmers ... about amyloid in an article published in the ...
... in southern and eastern Canada may disappear from most of ... the toll on their habitat that scientists predict in a ... Climate Change . Scientists looked at reservoirs of genetic ... stable habitats. They found that caribou populations in the most ...
... Excellence for Coral Reef Studies (CoECRS) at James Cook ... of the world,s biggest environmental problems. Dr Christina ... CoECRS, holds a joint position with the Center for ... Dr Hicks says more powerful economic interests, such as ...
Cached Biology News:Alzheimer substance may be the nanomaterial of tomorrow 2Climate change threatens genetic diversity, future of world's caribou 2Linking social science and ecology to solve the world's environmental problems 2
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Request Info...
Request Info...
Biology Products: